Nidanilimab

Item number	Size	Datasheet	Manual	SDS	Delivery time	Price
TGM-T76873-1mg	1 mg				7 - 10 business days*	229.00€
TGM-T76873-5mg	5 mg				7 - 10 business days*	712.00€
TGM-T76873-10mg	10 mg				7 - 10 business days*	1,118.00€
TGM-T76873-25mg	25 mg	-	-	-	7 - 10 business days*	1,659.00€
TGM-T76873-50mg	50 mg	-	-	-	7 - 10 business days*	2,228.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value... more

Close menu

Product information "Nidanilimab"

Description: Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1alpha and IL1beta signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). Target: IL Receptor, Interleukin. References: Rydberg Millrud C, et, al. Blockade of IL-1alpha and IL-1beta signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.